Overview

Latanoprost Versus Fotil

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.
Phase:
Phase 4
Details
Lead Sponsor:
Pharmaceutical Research Network
Treatments:
Latanoprost